{
    "clinical_study": {
        "@rank": "131250", 
        "arm_group": {
            "arm_group_label": "Healthy volunteers", 
            "arm_group_type": "Other", 
            "description": "Healthy volunteers taking a single dose of bosutinib and  a single dose of bosutinib plus aprepitant in random order"
        }, 
        "brief_summary": {
            "textblock": "This is an open label, randomized, single dose, one cohort, two sequence, two period\n      crossover study in healthy subjects.  The primary objective of the study is to evaluate the\n      effect of a single oral dose of aprepitant on the pharmacokinetic (PK) profile of a single\n      oral dose of bosutinib in healthy subjects."
        }, 
        "brief_title": "A Drug Interaction Study Between Bosutinib And Aprepitant In Healthy Volunteers", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male and/or female subjects with an informed consent document signed and\n             dated by the subject.\n\n        Exclusion Criteria:\n\n          -  Evidence or history of clinically significant hematological, renal, endocrine,\n             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or\n             allergic disease\n\n          -  Pregnant or nursing females; females of childbearing potential who are unwilling or\n             unable to use an acceptable method of non hormonal contraception as outlined in this\n             protocol .\n\n          -  Use of prescription or nonprescription drugs and dietary supplements within 7 days or\n             5 half lives (whichever is longer) prior to the first dose of study medication."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02058277", 
            "org_study_id": "B1871041"
        }, 
        "intervention": {
            "arm_group_label": "Healthy volunteers", 
            "description": "Single dose of bosutinib (500 mg) or single dose of bosutinib (500 mg) and aprepitant (125 mg)", 
            "intervention_name": "bosutinib or bosutinib + aprepitant", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Aprepitant"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "bosutinib", 
            "aprepitant", 
            "drug interaction", 
            "healthy volunteers", 
            "pharmacokinetics", 
            "chronic myelogenous leukemia"
        ], 
        "lastchanged_date": "May 19, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1871041&StudyName=A%20Drug%20Interaction%20Study%20Between%20Bosutinib%20And%20Aprepitant%20In%20Healthy%20Volunteers"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "DeLand", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "32720"
                }, 
                "name": "Pfizer Investigational Site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-Label, Randomized, 2-Period Crossover Study To Evaluate The Effect Of A Single Dose Of Aprepitant, A Moderate CYP3A Inhibitor On Bosutinib Administered Orally To Healthy Subjects", 
        "overall_contact": {
            "last_name": "Pfizer CT.gov Call Center", 
            "phone": "1-800-718-1021"
        }, 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "AUC is a measure of the plasma concentration of the drug over time. It is used to characterize drug absorption.", 
                "measure": "Area under the Concentration-Time Curve (AUC)", 
                "safety_issue": "No", 
                "time_frame": "96 hours"
            }, 
            {
                "description": "Cmax is the peak concentration.", 
                "measure": "Maximum Observed Plasma Concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "96 hours"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02058277"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)", 
                "measure": "Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)", 
                "safety_issue": "No", 
                "time_frame": "96 hours"
            }, 
            {
                "description": "Tmax is measure how fast a drug is absorbed", 
                "measure": "Time to Reach Maximum Observed Plasma Concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "96 hours"
            }, 
            {
                "description": "Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.", 
                "measure": "Plasma Decay Half-Life (t1/2)", 
                "safety_issue": "No", 
                "time_frame": "96 hours"
            }, 
            {
                "description": "Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.  Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling.  Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.", 
                "measure": "Apparent Oral Clearance (CL/F)", 
                "safety_issue": "No", 
                "time_frame": "96 hours"
            }, 
            {
                "description": "Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.", 
                "measure": "Apparent Volume of Distribution (Vz/F)", 
                "safety_issue": "No", 
                "time_frame": "96 hours"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}